Africa needs seven-fold rise in COVID-19 vaccine shipments

Brazzaville – COVID-19 vaccine shipments to Africa must rise by over seven times from around 20 million per month to 150 million each month on average if the continent is to fully vaccinate 70% of its people by September 2022.

The 70% target was agreed at the global COVID-19 summit hosted by the United States of America on the margins of the United Nations General Assembly this week. 

At the summit, the United States pledged to share 500 million more COVID-19 vaccines to low-income countries over the next year, bringing its total pledges to more than 1.1 billion doses. 

“The global COVID-19 summit was a dose of hope for Africa and we commend pledges to share more vaccines, save lives and build back better. It is the kind of international solidarity that will help to end the pandemic. This is about life and death for potentially millions of Africans so there is no time to waste in getting these shipments moving,” said Dr Matshidiso Moeti, World Health Organization (WHO) Regional Director for Africa. 

The COVAX Facility, the global platform to ensure equitable access to COVID-19 vaccines, has been forced to slash planned deliveries to Africa by 25% this year, due to global supply shortages and export bans. COVAX shipments are still coming into African countries – with 4 million doses received in the past week. However, only a third of the vaccines that wealthy countries pledged to share with Africa by the end of 2021 have been received. 

“Actions speak far louder than words and African countries need clear delivery dates so they can plan properly. We also need strong structures set up to ensure that all promises made are promises kept,” said Dr Moeti. 

WHO has assisted 18 African countries in conducting intra-action reviews, which analyse all aspects of their vaccination campaigns and offer recommendations. The reviews have shown that vaccine supply security and uncertainty around deliveries have been a major impediment for many African countries. Also, the longer the delay in rolling out the vaccines, the greater the risk of additional challenges emerging such as variants, hesitancy, operational gaps or other threats.

While Africa’s third wave continues to ease, 108 000 new cases were recorded, and more than 3000 lives lost in the week to 19 September. There have now been nearly 8.2 million COVID-19 cases recorded on the continent. The Delta variant has been found in 38 African countries. The Alpha variant has been detected in 45 countries and the Beta in 40.  

“Health workers, services and communities can and should use this time to regroup and prepare for the next wave. With end-of-year travel and festive celebrations fast approaching, fresh increases in cases should be expected in the coming months. Without widespread vaccination and other preventive measures, the continent’s fourth wave is likely to be the most brutal yet,” said Dr Moeti.

The WHO Regional Office for Africa held a virtual press conference today facilitated by APO Group. During the briefing Dr Benido Impouma, Programme Director for Universal Health Coverage/Communicable and Noncommunicable Disease, WHO Regional Office for Africa, was joined by Professor Jean-Jacques Muyembe, Director-General, National Institute for Biomedical Research (INRB), Democratic Republic of the Congo and Technical Secretary of the Multisectoral Committee for the Response to COVID-19 in DRC, and Dr Githinji Gitahi, Group Chief Executive Officer, AMREF Health Africa.

Also on hand to respond to questions were Dr Richard Mihigo, Coordinator, Immunization and Vaccines Development Programme, WHO Regional Office for Africa, and Dr Thierno Balde, Regional COVID-19 Deputy Incident Manager, WHO Regional Office for Africa.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
NEJM: Modern's vaccine is more effective than Pfizer's thumbnail

NEJM: Modern's vaccine is more effective than Pfizer's

במחקר חדש שפורסם אתמול (ד') ב-New England Journal of Medicine  ושעליו דיווח "ניו יורק טיימס", נעשתה השוואה "בעולם האמיתי" בין יעילות תרכיב החיסון של חברת פייזר לעומת זה של חברת מודרנה. בעת ששני התרכיבים החדשניים המבוססים עלmRNA  קיבלו אישור לשימוש נאמר שמבחינת היעילות שניהם שווים. אלא שעתה מתברר מהמחקר החדש שהנתונים מעידים מעט אחרת: יש…
Read More
Very Young Children in HIV Treatment More Likely to Die thumbnail

Very Young Children in HIV Treatment More Likely to Die

HIV/AIDS > HIV/AIDS — PEPFAR data show particularly high risk for infants despite antiretroviral treatment by Sophie Putka, Enterprise & Investigative Writer, MedPage Today November 30, 2023 Children younger than age 5 years with HIV who received antiretroviral treatment (ART) died globally at percentages two to nine times higher than older children, a CDC study
Read More
Hanseníase: o segundo lugar do ranking que não queremos ocupar no Brasil thumbnail

Hanseníase: o segundo lugar do ranking que não queremos ocupar no Brasil

Avalie o nosso conteúdo: Houve um erro fazendo sua requisição, por favor tente novamente! Obrigado!Sua avaliação é fundamental para que a gente continue melhorando o Portal Pebmed O Portal PEBMED é destinado para médicos e demais profissionais de saúde. Nossos conteúdos informam panoramas recentes da medicina. Caso tenha interesse em divulgar seu currículo na internet,…
Read More
Index Of News
Total
0
Share